News
PMCPA News
Press releases appear below, filter by date.
Mr William Harbage QC, Chair of the Code of Practice Appeal Board
Press release: 14 July 2020
Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded
Press release: 25 June 2020
LAUNCH OF ABPI CONSULTATION ON PROPOSALS FOR THE ABPI CODE OF PRACTICE 2021
Press release: 19 June 2020
PMCPA COVID-19 update
Press release: 18 March 2020
Daiichi-Sankyo, GW Pharmaceuticals, Bayer plc, Proveca Ltd, Otsuka UK & Otsuka Europe named in advertisements for breach of the ABPI Code of Practice
Press release: 27 July 2019
MHRA Guidance - Updates to prescribing information for centrally approved products in the event of the UK leaving the EU with no deal
Press release: 10 April 2019
Sunovion and Shield named in advertisements for breach of ABPI Code of Practice
Press release: 17 December 2018
Astellas Pharmaceuticals Ltd named in advertisements for breach of ABPI Code of Practice
Press release: 17 December 2018
Disclosure UK
Press release: 10 December 2018
Disclosure template for 2018 data submissions
ABPI Code of Practice for the Pharmaceutical Industry 2019 published
Press release: 06 December 2018
Proposals to amend the ABPI Code of Practice 2016 and the PMCPA Constitution and Procedure were agreed by ABPI members on 4 December 2018.
PMCPA Annual Report 2017
Press release: 04 December 2018
The report covers details of complaints made in 2017 and considered by the PMCPA in relation to the ABPI Code of Practice for the Pharmaceutical Industry. How many were received, who made them, their outcomes and sanctions
Thame Laboratories named in advertisement for breach of ABPI Code of Practice
Press release: 15 October 2018
The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Thame Laboratories was required to issue a corrective statement to recipients of the letter at issue.